We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies

Crb4.0

Cerebrolysin Research

Mostly mechanism / observational

83 peer-reviewed studies

What the evidence says

Mostly mechanism / observational

Most Cerebrolysin studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.

Most evidence is from high-quality meta-analyses and randomised trials published 1990–2026 with a typical study size of 143 participants.

Based on 83 studies · 15 meta-analyses · 61 RCTs · 9,818 total participants

Confidence

High confidence

By outcome

Stroke & recovery
Mostly mechanism / observational35 studies
Cognitive functionA peptide preparation studied as an adjunct in vascular dementia and post-stroke cognition; signals are weak and low-quality, and a Cochrane review found no proven benefit in acute stroke. · Weeks of IM/IV courses in trials (benefit unproven)
Mostly mechanism / observational27 studies
Neuroprotection & brain agingProposed BDNF/GDNF-like neurotrophic and neuroprotective activity; studied after stroke and TBI with small/mixed functional gains and no mortality benefit. · Not established
Mostly mechanism / observational16 studies
Traumatic brain injury
Mostly mechanism / observational12 studies
Safety profile
Mostly mechanism / observational4 studies

Steady research

24 studies in the last 5 years · Latest meta-analysis: 2026

199020082026

1Meta-Analysis2015

Gauthier S, Proaño JV, Jia J, Froelich L, Vester JC, Doppler E · Dement Geriatr Cogn Disord (2015)

Cerebrolysin Research

Mostly mechanism / observational

Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials.

Cerebrolysin for functional recovery in patients with acute ischemic stroke: a meta-analysis of randomized controlled trials.

Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer's disease.

Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series.

A meta-analysis of the effect of different neuroprotective drugs in management of patients with traumatic brain injury.

Efficacy and Safety of Cerebrolysin for Acute Ischemic Stroke: A Meta-Analysis of Randomized Controlled Trials.

The Efficacy and Safety of Alzheimer's Disease Therapies: An Updated Umbrella Review.

Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials.

Cerebrolysin for vascular dementia.

European Academy of Neurology and European Federation of Neurorehabilitation Societies guideline on pharmacological support in early motor rehabilitation after acute ischaemic stroke.

Safety and efficacy of Cerebrolysin in motor function recovery after stroke: a meta-analysis of the CARS trials.

Cerebrolysin for acute ischaemic stroke.

Evidence-Based Review of Randomized Controlled Trials of Interventions for Mental Health Management Post-Moderate to Severe Traumatic Brain Injury.

Nutritional interventions to support acute mTBI recovery.

Pharmacologic Neuroprotection for Functional Outcomes After Traumatic Brain Injury: A Systematic Review of the Clinical Literature.

Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial.

Efficacy and safety of cerebrolysin in neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIN II trial.

Cerebrolysin combined with rehabilitation promotes motor recovery in patients with severe motor impairment after stroke.

Randomized, placebo-controlled, double-blind, pilot trial to investigate safety and efficacy of Cerebrolysin in patients with aneurysmal subarachnoid hemorrhage.

[Effects of simultaneous use of Cerebrolysin and alteplase on hemorrhagic transformation of brain infarction and functional outcome in stroke patients: CEREHETIS, a randomized, multicenter pilot trial].